Core Viewpoint - Xenon Pharmaceuticals reported a narrower loss per share for Q4 2024 compared to the previous year, but did not generate any revenues due to the absence of marketed products [1][2][8] Financial Performance - The company reported a loss of 84 cents per share in Q4 2024, which is an improvement from a loss of 64 cents per share in the same quarter last year [1] - For the full year 2024, Xenon recorded a loss per share of $3.01, which is narrower than the Zacks Consensus Estimate of a loss of $3.10 [8] - Research and development (R&D) expenses increased by 45% to $59.5 million in Q4 2024, up from $41.1 million in the prior year [5] - General and administrative expenses rose by 43% year over year to $18 million, driven by higher personnel costs and consulting fees [6] Revenue Generation - Xenon did not recognize any revenues in Q4 2024 or in the year-ago quarter, primarily due to the lack of marketed products [2][8] - The company has ongoing collaboration revenues from its partnership with Neurocrine Biosciences for NBI-921352, but no revenues were recognized from this collaboration in the reported quarter [2][3] Pipeline Development - Xenon is developing azetukalner for treating focal onset seizures and has initiated phase III studies, with top-line data expected in the second half of 2025 [10] - The company is also evaluating azetukalner for primary generalized tonic-clonic seizures and has plans for a late-stage bipolar depression program [12][14] - A phase II proof-of-concept study for azetukalner in major depressive disorder (MDD) has been completed, leading to the initiation of phase III studies [13][15] - The company is collaborating with the Icahn School of Medicine for an ongoing phase II study of azetukalner in MDD [15] Cash Position - As of December 31, 2024, Xenon had cash, cash equivalents, and marketable securities totaling $754.4 million, down from $803.3 million as of September 30, 2024 [7] - The company expects its cash balance to support its operating plans through 2027, including ongoing clinical studies [7]

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Gilead Sciences (GILD) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Gilead currently has an average bro ...

Core Insights - Acadia Pharmaceuticals reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate of 19 cents, and adjusted for a one-time sale of a Rare Pediatric Disease Priority Review Voucher [1] - Total revenues for the quarter were $259.6 million, exceeding the Zacks Consensus Estimate of $255 million, with significant contributions from its two marketed products, Nuplazid and Daybue [2][4] Financial Performance - Revenues from Nuplazid increased 13% year over year to $162.9 million, surpassing the Zacks Consensus Estimate of $160.4 million [5] - Daybue recorded net product sales of $96.7 million, up 11% year over year, also beating the Zacks Consensus Estimate of $94.4 million [6] - For the full year 2024, Acadia's total revenues reached $957.8 million, a 32% increase year over year, exceeding the Zacks Consensus Estimate of $953.2 million [9] Expense Overview - Research and development (R&D) expenses rose 51% year over year to $100.7 million, primarily due to increased costs from clinical-stage programs [7] - Selling, general and administrative (SG&A) expenses increased 17% year over year to $130.1 million, attributed to higher marketing costs for Nuplazid and Daybue [8] Future Outlook - Acadia expects total revenues from U.S. sales of its products in 2025 to range between $1.030 billion and $1.095 billion, with Nuplazid sales projected between $650 million and $690 million, and Daybue sales expected between $380 million and $405 million [10][12] - R&D expenses for 2025 are projected to be between $310 million and $330 million, while SG&A expenses are expected to be between $535 million and $565 million [12] Product Development Updates - A regulatory filing for Daybue to treat Rett syndrome in the EU is under review, with approval expected in Q1 2026 [13] - Acadia plans to enroll the last patient in the phase III COMPASS PWS study for ACP-101 in Q4 2025, with top-line data expected in H1 2026 [14] - The company anticipates initiating a mid-stage study for ACP-204 for Lewy Body dementia psychosis in Q3 2025 [15] - Acadia signed a worldwide license agreement with Saniona to develop ACP711 for essential tremor, with a mid-stage study planned for 2026 [16][17]

Group 1 - Salesforce reported fiscal fourth-quarter revenue of $9.99 billion, an 8% year-over-year growth, which was slightly below analyst expectations [1] - Adjusted earnings per share for the fourth quarter were $1.75, compared to $1.74 a year earlier, but missed estimates [1] - Shares of Salesforce fell about 5% in extended trading following the earnings report, and have lost approximately 8% since the beginning of the year [3] Group 2 - For fiscal 2026, Salesforce projected full-year revenue between $40.5 billion and $40.9 billion, and adjusted EPS between $11.09 and $11.17, both below analyst consensus [2] - The analyst consensus for revenue was $41.32 billion and for EPS was $11.19 [2] - Salesforce announced that former Gilead Sciences CFO Robin Washington will join the company as chief operating and financial officer on March 21 [2]